CLU and myeloid sarcoma: revealed that, in patients with progressive MS and longstanding disease, white matter plaques were consistently positive for complement proteins (C3, Factor B, C1q), activation products (C3b, iC3b, C4d, TCC) and regulators (factor H, C1inh, Clusterin) (25).